We are heartbroken to share the news that Tassia Haines has died. A member of METUPUK and our Executive Lead for Wales, Tass had been a significant campaigner for MBC
Tassia Haines
PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline
Mindfulness and Metastatic Breast Cancer at Christmas
Living with an incurable form of cancer presents lots of physical, emotional and mental challenges not least of which are the expectations and pressures associated with annual celebrations and milestones;
Kit Dzeryn
Sadly our Kit @Diamondtrees11 died on Monday 7th May. Her husband Phillip contacted us with the tragic news. We didn’t meet Kit but she was an integral part of METUPUK
GIVEACAR and why they support METUPUK
In September last year, one of our Trustees Louise Furneaux died from metastatic breast cancer. She was a valued member of METUPUK and was our most recently appointed trustee. She
China Doll
Birthday and cancerversaries became bittersweet as I was dealing with the realities of cancer, the side effects, the constant fear of the unknown, the helplessness, the indignity of losing who you are, who you were, even things you take for granted like walking up your own stairs or getting out the bath (because the treatment has made you weak).
And so, I feel with every year I am living with MBC, with every new treatment and with every progression, I am like a china doll. Leaving broken pieces of me behind.
Breathing Techniques with Louisa from Breathe Balance Be
“As long as you are breathing, there is more right with you than there is wrong…..”
On the trail of a Clinical Trial…
METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the UK; Cancer Research UK, Be Part of Research, ISRCTN and ClinicalTrials.gov.
Leaping forward to 2022, surely by now one of them must be THE accurate, easily searchable source of breast cancer trials? If not, how do our oncologists quickly and accurately find the best trials for their metastatic patients?
And where do patients start when looking for a metastatic trial themselves?
Targeted treatment Piqray with Fulvestrant is approved
METUPUK welcomes the approval of Piqray (alpelisib) plus fulvestrant for the treatment of hormone receptor-positive, HER2-negative, PIK3CA- mutated advanced breast cancer.
Piqray is an exciting new cancer medicine because it is the first targeted treatment option for advanced breast cancer that has a PIK3CA mutation.
Trodelvy Now! Latest Update
METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior lines of systemic therapies. This follows on from the decision to approve Trodelvy in NHS Scotland in March 2022. Wales and Northern Ireland normally follow decisions by NHS England and we hope that Trodelvy will be made available to every patient who is eligible without delay.